(LLY) Lilly Alzheimer Drug Misses Goals; Secondary Analysis Shows Promise Aug 24 at 07:30
(LLY) Eli Lilly and Company Announces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer's Disease
(LLY) Eli Lilly & Co.'s Solanezumab Phase 3 Clinical Trials for Alzheimer's Disease Fail to Meet Primary Endpoints Aug 24 at 07:18
***DISCLOSURE: Long (LLY) From pre market levels $44.50 Easily cleared the 45 level, at 2008 highs
Thanks for checking - Feel free to contact me regarding trading
services, education and access to my daily guest appearance broadcast.
This material is being provided to you for educational purposes only. No information presented constitutes a recommendation by Legend Trading or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy. The content neither is, nor should be construed as, an offer, or a solicitation of an offer, to buy, sell, or hold any securities. You are fully responsible for any investment decisions you make. Such decisions should be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance and liquidity needs.